Drug Profile

Alpha-dihydrotetrabenazine

Alternative Names: (+)-Alpha-Dihydrotetrabenazine; (+)-α-DHTBZ; ADE-513; HTBZ

Latest Information Update: 12 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adeptio Pharmaceuticals
Developer Adeptio Pharmaceuticals; University of Michigan
Class Quinolizines; Small molecules
Mechanism of Action Dopamine receptor antagonists; Vesicular monoamine transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

16 Apr 2024 Adeptio Pharmaceuticals initiates a phase II trial in Tardive dyskinesia in Czech Republic (PO) (CTIS2023-509518-12-01) (EUCT=2023-509518-12-01)
27 Dec 2022 Phase-II clinical trials in Tardive dyskinesia (In the elderly, In adults) in Czech Republic (PO) (EudraCT2022-001685-35)
02 Sep 2022 Phase-II clinical trials in Tardive dyskinesia (In adults, In the elderly) in Croatia (PO) (EudraCT2022-000271-39)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com